Clinical Comprehensive Evaluation of Lu Dangshen Oral Liquid in the Treatment of Lung Spleen Qi Deficiency Syndrome
10.19879/j.cnki.1005-5304.202507125
- VernacularTitle:潞党参口服液治疗肺脾气虚证临床综合评价
- Author:
Ruiyao LI
1
;
Gen LI
;
Yaqi ZU
;
Zhangyi LIU
;
Jinghua LI
;
Xudong TANG
Author Information
1. 天津中医药大学,天津 301617
- Publication Type:Journal Article
- Keywords:
Lu Dangshen Oral Liquid;
lung spleen qi deficiency syndrome;
clinical comprehensive evaluation;
multi criteria decision analysis
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2025;32(12):175-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct a clinical comprehensive evaluation of Lu Dangshen Oral Liquid from 6 dimensions,including safety,effectiveness,economic value,innovativeness,suitability and accessibility.Methods The clinical evidence of Lu Dangshen Oral Liquid and seven control drugs(Bufei Huoxue Capsules,Xiangsha Liujun Pills,Jinshuibao Capsules,Shenling Baizhu Granules,Yupingfeng Granules,Zhenqi Fuzheng Granules and Bailing Capsules)were obtained by using quantitative and qualitative methods through literature retrieval,questionnaire survey and data collection.Based on the multi criteria decision analysis(MCDA)model,the clinical value of drugs was comprehensively evaluated.The weights of criterion layer,index layer and alternative scheme were calculated by analytic hierarchy process.The equal frequency discretization rule was used to classify the evaluation results.Results The safety evidence showed that the main adverse reactions were epistaxis and nausea,and there were no serious adverse events.The comprehensive evaluation was grade A(the risk was controllable and the evidence was sufficient).Clinical studies showed that its treatment of lung spleen qi deficiency syndrome reflects the idea of treating different diseases with same method,and its efficacy in stable chronic obstructive pulmonary disease and children with recurrent respiratory tract infection was better than conventional treatment or Spleen Aminopeptide Oral Lyophilized Powder,and its effectiveness was rated as grade A.In terms of economy,the daily drug cost was relatively high,and it was rated as grade C.The preparation process was authorized by one patent.The single Chinese materia medica could improve the diseases and symptoms related to lung spleen qi deficiency syndrome,and the innovation was rated as grade A.In the questionnaire survey,the clinical use and patient compliance were excellent,and the suitability was rated as grade A.The supply of raw materials was stable,and the accessibility was rated as grade B.Conclusion The comprehensive evaluation of the clinical value of Lu Dangshen Oral Liquid in the treatment of lung spleen qi deficiency syndrome is grade A,which can provide references for the adjustment of the national medical insurance catalog and the national essential medicine catalog.
